Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMPV450)

• Drug Name: NIPECOTIC ACID Drug Info
• Synonyms: Piperidine-3-carboxylic acid; 498-95-3; h-dl-nip-oh; EINECS 207-873-9; CHEMBL277498; dl-piperidine-3-carboxylic acid; 60252-41-7; CHEBI:116931; XJLSEXAGTJCILF-UHFFFAOYSA-N; MFCD00005992; SR-01000075612; Nipecotic; h-nip-oh; 3-carboxypiperidine; (y)-Nipecotic acid; ( inverted exclamation markA)-Nipecotic acid; PubChem6793; D-nipecotic acid-HCl; h-dl-pic(3)-oh; (RS)-nipecotic acid

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 4498
  ChEBI ID: CHEBI:116931
  CAS Number: CAS 498-95-3
  TTD Drug ID: DMPV450

Molecule-Related Drug Atlas

Drug(s) Targeting Adenosine A3 receptor (ADORA3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
IB-MECA	DM9G5XD	Psoriasis vulgaris	EA90	Phase 3	[6]
Tonapofylline	DMBH316	Acute and chronic heart failure	BD1Z	Phase 2	[7]
NITD609	DMQHBSX	Malaria	1F40-1F45	Phase 2	[8]
CF102	DMP56WJ	Hepatocellular carcinoma	2C12.02	Phase 2	[9]
SCH-442416	DMQ2K1V	N. A.	N. A.	Phase 1	[10]
AST-004	DM5WMG7	Stroke	8B20	Phase 1	[11]
BEMESETRON	DMSPJX9	N. A.	N. A.	Discontinued in Phase 3	[2]
BAY 60-6583	DMTEJV1	Myocardial ischemia	BA6Z	Preclinical	[12]
CF602	DM0ULO2	Inflammation	1A00-CA43.1	Preclinical	[9]
CF502	DMQSJ20	Inflammation	1A00-CA43.1	Preclinical	[9]

Drug(s) Targeting GABA transporter-3 (SLC6A11)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
GSK683699	DMTW79H	Inflammatory bowel disease	DD72	Phase 2	[4]
Beta-Alanine	DMC64EI	Discovery agent	N.A.	Investigative	[13]
2,4-Diamino-butyric acid(GABA)	DMAOGBP	Discovery agent	N.A.	Investigative	[14]
4-Hydroxy-piperidine-3-carboxylic acid	DM9VQ0T	Discovery agent	N.A.	Investigative	[15]

Drug(s) Targeting GABA transaminase (ABAT)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
L-Alanine	DMZDN4W	Dietary shortage	5B5K	Approved	[16]
Pyridoxal Phosphate	DMO2K0J	Malnutrition	5B50-5B71	Approved	[16]
Pyruvic acid	DM7Q41G	Malnutrition	5B50-5B71	Approved	[16]
Vigabatrin	DMYT0OG	Alcohol dependence	6C40.2	Approved	[17]
Divalproex sodium	DM4RK0G	Seizure disorder	8A6Z	Approved	[16]
CPP-115	DMK9NQI	Tourette syndrome	8A05.00	Phase 2	[18]
K-828-AB	DMJLNZQ	Dementia	6D80-6D86	Phase 2	[19]
CPP -15	DMQCHU3	Infantile spasm	8A62.0	Phase 1	[18]
T83193	DMHO29Y	Discovery agent	N.A.	Patented	[20]
4-hydroxybenzaldehyde	DM471P5	Discovery agent	N.A.	Patented	[21]

Drug(s) Targeting GABA transporter GAT-1 (SLC6A1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tiagabine	DMKSQG0	Epilepsy	8A60-8A68	Approved	[22]
Metadoxine	DMM4QOJ	Multiple myeloma	2A83	Approved	[23]
GSK683699	DMTW79H	Inflammatory bowel disease	DD72	Phase 2	[24]
CI-966	DM8T2KA	Convulsion	8A68.Z	Phase 1	[25]
2,4-Diamino-butyric acid(GABA)	DMAOGBP	Discovery agent	N.A.	Investigative	[14]
LU32-176B	DM2YOVC	Discovery agent	N.A.	Investigative	[26]
(R)-nipecotic acid	DMWGB40	Discovery agent	N.A.	Investigative	[24]
4-Hydroxy-piperidine-3-carboxylic acid	DM9VQ0T	Discovery agent	N.A.	Investigative	[15]
(R/S) EF-1500	DMYDG27	Discovery agent	N.A.	Investigative	[22]
(R)-EF-1520	DM297MU	Discovery agent	N.A.	Investigative	[22]

Drug(s) Targeting Gamma-aminobutyric acid receptor (GAR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Phenobarbital	DMXZOCG	Cluster headache	8A81.0	Approved	[16]
Allopregnanolone	DMNLHAC	Depression	6A70-6A7Z	approved	[27]
THIOCOLCHICOSIDE	DMEPWYA	Muscle spasm	MB47.3	Approved	[28]
Clonazepam	DMTO13J	Absence epilepsy		Approved	[29]
Piperazine	DMTY9LU	Ascariasis	1F62	Approved	[30]
Alpidem	DMN7Y9K	Anxiety disorder	6B00-6B0Z	Approved	[31]
Moxidectin	DMYGHX5	Onchocerciasis	1F6A	Approved	[32]
DP-VPA	DMGOXPQ	Bipolar disorder	6A60	Approved	[33]
ANDROSTERONE	DMITJAK	N. A.	N. A.	Phase 3	[27]
ZK-93423	DMFWMKZ	Epileptic seizures	8A61-8A6Z	Phase 3	[34]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Adenosine A3 receptor (ADORA3)	TTJFY5U	AA3R_HUMAN	Inhibitor	[2]
GABA transaminase (ABAT)	TTT2LD9	GABT_HUMAN	Inhibitor	[3]
GABA transporter GAT-1 (SLC6A1)	TTPRKM0	SC6A1_HUMAN	Inhibitor	[4]
GABA transporter-3 (SLC6A11)	TT8RXO5	S6A11_HUMAN	Inhibitor	[4]
Gamma-aminobutyric acid receptor (GAR)	TTNJYV2	NOUNIPROTAC	Inhibitor	[5]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4564).
• [2] 2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacolog... J Med Chem. 2005 Nov 3;48(22):6887-96.
• [3] Aminomethyl-1,2,4-benzothiadiazines as potential analogues of gamma-aminobutyric acid. Unexpected discovery of a taurine antagonist. J Med Chem. 1982 Feb;25(2):113-6.
• [4] Epimeric cis-decahydroquinoline-5-carboxylic acids: effects on gamma-aminobutyric acid uptake and receptor binding in vitro. J Med Chem. 1981 Jul;24(7):788-94.
• [5] Orally active and potent inhibitors of gamma-aminobutyric acid uptake. J Med Chem. 1985 May;28(5):653-60.
• [6] A role for central A3-adenosine receptors. Mediation of behavioral depressant effects. FEBS Lett. 1993 Dec 20;336(1):57-60.
• [7] 2-Amino-5-benzoyl-4-phenylthiazoles: Development of potent and selective adenosine A1 receptor antagonists. Bioorg Med Chem. 2010 Mar 15;18(6):2195-2203.
• [8] Spiroindolones, a potent compound class for the treatment of malaria. Science. 2010 Sep 3;329(5996):1175-80.
• [9] 2011 Pipeline of Can-Fite BioPharm.
• [10] Synthesis and evaluation of 1,2,4-triazolo[1,5-c]pyrimidine derivatives as A2A receptor-selective antagonists. Bioorg Med Chem Lett. 2010 Oct 1;20(19):5690-4.
• [11] Adenosine A1R/A3R (Adenosine A1 and A3 Receptor) Agonist AST-004 Reduces Brain Infarction in a Nonhuman Primate Model of Stroke. Stroke. 2022 Jan;53(1):238-248.
• [12] Protein kinase C protects preconditioned rabbit hearts by increasing sensitivity of adenosine A2b-dependent signaling during early reperfusion. J Mol Cell Cardiol. 2007 Sep;43(3):262-71.
• [13] Stable expression of a neuronal gamma-aminobutyric acid transporter, GAT-3, in mammalian cells demonstrates unique pharmacological properties and ion dependence. Mol Pharmacol. 1994 Sep;46(3):550-7.
• [14] Glycine antagonists. Synthesis, structure, and biological effects of some bicyclic 5-isoxazolol zwitterions. J Med Chem. 1986 Feb;29(2):224-9.
• [15] Hydroxy- and amino-substituted piperidinecarboxylic acids as gamma-aminobutyric acid agonists and uptake inhibitors. J Med Chem. 1982 Oct;25(10):1157-62.
• [16] DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6.
• [17] Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
• [18] Clinical pipeline report, company report or official report of Catalyst Pharma.
• [19] Phase II clinical trial of K-828-AB for treating behavioral and psychological symptoms of dementia. Kowa Co. Ltd.
• [20] Inhibition of GABA shunt enzymes' activity by 4-hydroxybenzaldehyde derivatives. Bioorg Med Chem Lett. 2006 Feb;16(3):592-5.
• [21] Inactivation of GABA transaminase by 3-chloro-1-(4-hydroxyphenyl)propan-1-one. Bioorg Med Chem Lett. 2009 Feb 1;19(3):731-4.
• [22] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 929).
• [23] Company report (Alcobra pharma)
• [24] Novel secoergoline derivatives inhibit both GABA and glutamate uptake in rat brain homogenates: synthesis, in vitro pharmacology, and modeling. J Med Chem. 2004 Nov 4;47(23):5620-9.
• [25] Tiagabine, SK&F 89976-A, CI-966, and NNC-711 are selective for the cloned GABA transporter GAT-1. Eur J Pharmacol. 1994 Oct 14;269(2):219-24.
• [26] First demonstration of a functional role for central nervous system betaine/{gamma}-aminobutyric acid transporter (mGAT2) based on synergistic anti... J Pharmacol Exp Ther. 2005 Feb;312(2):866-74.
• [27] Neurosteroid analogues. 11. Alternative ring system scaffolds: gamma-aminobutyric acid receptor modulation and anesthetic actions of benz[f]indenes. J Med Chem. 2006 Jul 27;49(15):4595-605.
• [28] 3-demethoxy-3-glycosylaminothiocolchicines: Synthesis of a new class of putative muscle relaxant compounds. J Med Chem. 2006 Sep 7;49(18):5571-7.
• [29] Glutamate- and GABA-based CNS therapeutics. Curr Opin Pharmacol. 2006 Feb;6(1):7-17.
• [30] Cyclooctadepsipeptides--an anthelmintically active class of compounds exhibiting a novel mode of action. Int J Antimicrob Agents. 2003 Sep;22(3):318-31.
• [31] Synthesis and binding affinity of 2-phenylimidazo[1,2-alpha]pyridine derivatives for both central and peripheral benzodiazepine receptors. A new se... J Med Chem. 1997 Sep 12;40(19):3109-18.
• [32] 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
• [33] DP-VPA D-Pharm. Curr Opin Investig Drugs. 2002 Jun;3(6):921-3.
• [34] Structural requirements for agonist actions at the benzodiazepine receptor: studies with analogues of 6-(benzyloxy)-4-(methoxymethyl)-beta-carbolin... J Med Chem. 1990 Mar;33(3):1062-9.